Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
424studies shown
Showing 301-325 of 424
CompletedNCT02167724

Multicentre Evaluation of Bucco-dental Health in Patients With Schizophrenia in Côte d'Or

This study exists to learn from real-world information that can show how questionnaires and follow-up reports fits into care. Researchers are trying to understand what questionnaires and follow-up reports can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherOver 18 Years
Countries
France
Sponsor
Centre Hospitalier Universitaire Dijon
Condition
Schizophrenia
CompletedNCT03238326

Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

This study exists to understand how a medication treatment holds up over time after the earliest research stage. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted.

SchizophreniaOtherFrom 13 Years to 17 Years
Countries
France, Italy, Mexico, Poland, Romania, Russian Federation, Serbia, Spain, Ukraine, United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT01373866

Multimodal MRI-guided rTMS to Treat Refractory Hallucinations

This study exists to understand what helps brain scans or other body measurements work in everyday practice, not just under ideal conditions. Researchers are trying to understand what brain scans or other body measurements can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 13 Years to 60 Years
Countries
France
Sponsor
University Hospital, Lille
Condition
Schizophrenia
CompletedNCT02150174

Testing Effect and Schizophrenia

This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
France
Sponsor
University Hospital, Strasbourg, France
Condition
Schizophrenia
CompletedNCT02570594

Autobiographical Memory Organization in Schizophrenia

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
France
Sponsor
University Hospital, Strasbourg, France
Condition
Schizophrenia
CompletedNCT02744989

STIM'ZO : Examining tDCS as an add-on Treatment for Persistent Symptoms in Schizophrenia

This study exists to see whether a digital app or remote support tool is workable and worth testing more broadly. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
France, Monaco
Sponsor
Hospices Civils de Lyon
Condition
Schizophrenia
CompletedNCT02627716

Joint Crisis Plan Effectiveness in Preventing Relapses in Schizophrenia and Schizoaffective Disorder

This study exists to compare options and see whether questionnaires and follow-up reports offers something meaningfully different. Researchers are trying to understand whether questionnaires and follow-up reports can better prevent setbacks and support longer-term stability.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
France
Sponsor
University Hospital, Lille
Condition
Schizophrenia
CompletedNCT04846881

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

This study exists to learn from real-world information that can show how the medication Iclepertin fits into care. Researchers are trying to understand whether the medication Iclepertin can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
Argentina, Brazil, Chile, Croatia, France, Hungary, Japan, Malaysia, Netherlands, Poland, Romania, Serbia, Singapore, Slovakia, South Korea, Spain, Ukraine, United States
Sponsor
Boehringer Ingelheim
Condition
Schizophrenia
CompletedNCT02879604

Cost-utility Study of a Group of Compensatory Cognitive Remediation in Schizophrenia

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
France
Sponsor
University Hospital, Montpellier
Condition
Schizophrenia
CompletedNCT02664129

Video as a Tool to Improve Insight in Schizophrenia

This study exists to understand how a therapy or guided support program holds up over time after the earliest research stage. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
France
Sponsor
University Hospital, Montpellier
Condition
Schizophrenia
CompletedNCT03284138

Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of First Rank Symptoms (FRS) on Schizophrenia

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
France
Sponsor
Assistance Publique - Hôpitaux de Paris
Condition
Schizophrenia
TerminatedNCT02853019

Emotion and Motivation in Patients With Psychosis

This study exists to explore whether this type of care could improve care and understanding. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
France
Sponsor
University Hospital, Strasbourg, France
Condition
Schizophrenia
TerminatedNCT05501405

Brain and Oculometric Markers of Emotional Facial Expression Recognition Deficits

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 10 Years to 50 Years
Countries
France
Sponsor
Hôpital le Vinatier
Condition
Schizophrenia
TerminatedNCT06397950

Correlates of Fatigue in People With Schizophrenia

This study exists to compare options and see whether smoking support or smoking-related treatment offers something meaningfully different. Researchers are trying to understand whether smoking support or smoking-related treatment can better support energy, concentration, and everyday functioning.

SchizophreniaOtherOver 18 Years
Countries
France
Sponsor
GCS CIPS
Condition
Schizophrenia
CompletedNCT04025905

Social Cognition Training and Vocational Rehabilitation

This study exists to understand how questionnaires and follow-up reports holds up over time after the earliest research stage. Researchers are trying to understand whether questionnaires and follow-up reports can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
France
Sponsor
Hôpital le Vinatier
Condition
Schizophrenia
Not Yet RecruitingNCT06974513

Auditory Localization in Schizophrenia

This study exists to see whether a digital app or remote support tool can make care clearer and more responsive. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 35 Years
Countries
France
Sponsor
Hôpital le Vinatier
Condition
Schizophrenia
TerminatedNCT03351244

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand whether this type of care can better prevent setbacks and support longer-term stability.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
Canada, France, Japan, South Korea, Spain, Taiwan, United States
Sponsor
Boehringer Ingelheim
Condition
Schizophrenia
CompletedNCT03345342

A Study of Paliperidone Palmitate 6-Month Formulation

This study exists to explore whether the medication Paliperidone could improve care and understanding. Researchers are trying to understand whether the medication Paliperidone can better prevent setbacks and support longer-term stability.

SchizophreniaOtherFrom 18 Years to 70 Years
Countries
Argentina, Australia, Brazil, Bulgaria, Czech Republic, France, China, Hungary, India, Italy, Malaysia, Mexico, Poland, Russian Federation, South Africa, South Korea, Spain, Taiwan, Turkey, Ukraine, United States
Sponsor
Janssen Research & Development, LLC
Condition
Schizophrenia
CompletedNCT00460512

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia

This study exists to understand whether the medication Flexibly is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to the medication Flexibly in practice and what may need to be adjusted.

SchizophreniaOtherOver 18 Years
Countries
Belgium, Bulgaria, Croatia, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Latvia, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Serbia, Spain, Sweden, Switzerland, Turkey, United Kingdom
Sponsor
Janssen-Cilag International NV
Condition
Schizophrenia
CompletedNCT02713282

A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation

This study exists to explore whether the medication Transition could improve care and understanding. Researchers are trying to understand whether the medication Transition can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
Croatia, Denmark, France, Germany, Greece, Israel, Malaysia, Netherlands, Russian Federation, Saudi Arabia, South Korea, Spain, Taiwan, Turkey, United Kingdom
Sponsor
Janssen-Cilag Ltd.
Condition
Schizophrenia
CompletedNCT03809325

A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly

This study exists to explore whether questionnaires and follow-up reports could improve care and understanding. Researchers are trying to understand what questionnaires and follow-up reports could change in day-to-day care and decision-making.

SchizophreniaOtherOver 18 Years
Countries
Belgium, France, Germany, Hungary, Italy, Spain, United Kingdom
Sponsor
Janssen-Cilag International NV
Condition
Schizophrenia
RecruitingNCT04278339

Study of Electrophysiological Markers Related to the Cognitive and Affective Processes Behind Empathic Behaviour in Schizophrenic Spectrum Disorder

This study exists to explore whether the medication Electrophysiological could improve care and understanding. Researchers are trying to understand whether the medication Electrophysiological can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
France
Sponsor
Centre Hospitalier Universitaire de Nice
Condition
Schizophrenia
RecruitingNCT04871048

Examining tDCS Effect on Cannabis Use Disorder in Patients With Schizophrenia

This study exists to understand what helps smoking support or smoking-related treatment work in everyday practice, not just under ideal conditions. Researchers are trying to understand whether smoking support or smoking-related treatment can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
France
Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Condition
Schizophrenia